Mayo Clinic Q&A podcast: COVID-19 and multisystem inflammatory syndrome in children

Children can become ill with COVID-19, and sometimes they develop a rare but serious reaction called multisystem inflammatory syndrome in children (MIS-C).

October 9, 2020

Mayo Clinic

Overview

Multisystem inflammatory syndrome in children (MIS-C) is a serious condition associated with COVID-19, characterized by inflammation of multiple organ systems. As of August 2020, over 600 cases were reported in the U.S., predominantly affecting minority populations.

Background

MIS-C is a rare but severe postinfectious hyperinflammatory disorder that can lead to significant morbidity in children following COVID-19 infection. Understanding its epidemiology, clinical presentation, and treatment strategies is crucial for pediatric healthcare providers, especially given its disproportionate impact on minority populations. The condition shares similarities with Kawasaki disease, complicating diagnosis and management.

Data Highlights

No numerical data available in the source material.

Key Findings

MIS-C typically presents 2 to 4 weeks after COVID-19 infection.
Common symptoms include persistent fever, shock, and multiorgan involvement.
Over 70% of reported cases are among Hispanic/Latino and non-Hispanic Black children.
Diagnostic criteria include fever, laboratory evidence of inflammation, and involvement of two or more organ systems.
Management often involves IVIG and corticosteroids, with a focus on multidisciplinary care.

Clinical Implications

Healthcare providers should be vigilant for signs of MIS-C in children with a history of COVID-19, particularly in minority populations. Early recognition and multidisciplinary management are essential for improving outcomes in affected children.

Conclusion

MIS-C remains a critical concern in pediatric care during the COVID-19 pandemic, necessitating ongoing research and awareness among healthcare professionals.